Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970410 · ClinicalTrials.gov registry record · Phase 4
Main Study: Switch Sub-study: Switch-jcv
A Phase 4 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT01970410 is a Phase 4 study that has completed, run by Providence Health & Services. The registered enrollment target is 55 participants.
The verdict
NCT01970410, a Phase 4 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
MAIN STUDY: The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for PML. This is a two center interventional study of patients who have had 12 or more continuous infusions of natalizumab , who are anti-JCV-ab positive, and who had been free of clinical relapses during prior 12 months of natalizumab therapy who will be switching to teriflunomide. SUB-STUDY: To study the number of patients experiencing a reduction in the anti-JCV antibody Index value in patients who had received at least one dose of teriflunomide during participation in the SWITCH protocol (main study).
Interventions
- DRUG teriflunomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2013-10 |
| Est. Completion | 2022-02-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01970410
The ClinicalTrials.gov registry entry for NCT01970410 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which teriflunomide is the first listed.
NCT01970410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01970410 about?
NCT01970410 is a clinical study titled "Main Study: Switch Sub-study: Switch-jcv". MAIN STUDY: The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for PML. This is a two center interventional study of patients who have ha...
What is the current status of trial NCT01970410?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2013-10. Estimated completion is 2022-02-14.
What interventions are being tested in trial NCT01970410?
The interventions under investigation include: teriflunomide (DRUG).
Who is sponsoring clinical trial NCT01970410?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.